Drug Profile
Muscular dystrophy gene therapy - Asklepios BioPharmaceutical
Alternative Names: Biostrophin; rAAV2.5-CMV-minidystrophin (d3990)Latest Information Update: 27 May 2021
Price :
$50
*
At a glance
- Originator Asklepios BioPharmaceutical
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Duchenne muscular dystrophy
Most Recent Events
- 07 Oct 2010 Adverse events data from a phase I trial in Duchenne muscular dystrophy released by AskBio
- 10 Oct 2006 Asklepios has entered into a cross-agreement with GSK to develop and commercialise gene therapy treatments for a variety of indications, including muscular dystrophy
- 29 Mar 2006 Phase-I clinical trials in Duchenne muscular dystrophy in USA (IM)